Bilateral Inflammatory Breast Cancer That Developed Two Years after Treatment for Triple-negative Breast Cancer

Intern Med. 2022 Aug 1;61(15):2387-2391. doi: 10.2169/internalmedicine.7786-21. Epub 2022 Jan 13.

Abstract

A 66-year-old woman underwent partial mastectomy and a sentinel lymph node biopsy for left breast cancer; the pathological diagnosis was invasive ductal carcinoma (pT1aN0, pStage I, triple-negative subtype). Postoperative radiotherapy was performed. Two years later, she developed redness and induration at both breasts. The diagnosis was bilateral inflammatory breast cancer. After four cycles of dose-dense epirubicin and cyclophosphamide followed by 12 weekly paclitaxel cycles, bilateral total mastectomy and axillary lymph node dissection were performed. At the one-year follow-up after undergoing operation and radiotherapy, she remained alive without recurrence. Dose-dense treatment regimens may help patients achieve complete resection without short-term recurrence.

Keywords: bilateral inflammatory breast cancer; dose-dense chemotherapy; triple-negative breast cancer.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms* / drug therapy
  • Epirubicin / adverse effects
  • Female
  • Humans
  • Inflammatory Breast Neoplasms* / surgery
  • Lymph Node Excision
  • Mastectomy
  • Sentinel Lymph Node Biopsy
  • Triple Negative Breast Neoplasms* / surgery

Substances

  • Epirubicin